[1] 王巨威,王静,马丽君,等. 基于JoinPoint回归模型的2000-2019年我国肝癌发病与死亡变化趋势[J]. 中国癌症防治杂志,2024,16(2):180-185. [2] Su X, Li Y, Ren Y, et al. A new strategy for overcoming drug resistance in liver cancer: epigenetic regulation[J]. Biomed Pharmacother,2024,176:116902. [3] 林孔英,陈清静,郭洛彬,等. 甲胎蛋白反应评估中晚期肝癌靶免联合治疗效果和预后的多中心临床研究[J]. 中华消化外科杂志,2024,23(2):248-256. [4] 武雯雯,仇艳坤. 慢性乙型肝炎患者二维剪切波肝脏弹性成像定量和外周血ALP/PLT比值的变化研究[J]. 实用肝脏病杂志,2024,27(1):24-27. [5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志,2020,19(1):1-20. [6] Moazzam Z, Alaimo L, Endo Y, et al. Variations in textbook oncologic outcomes after curative-intent resection: early versus intermediate hepatocellular carcinoma based on barcelona clinic liver cancer criteria and Child-Pugh classification[J]. Ann Surg Oncol,2023,30(2):750-759. [7] Liu H, Fu Y, Guo D, et al. TMM: A comprehensive CAD system for hepatic fibrosis 5‐grade METAVIR staging based on liver MRI[J]. Med Phys,2024,51(3):2032-2043. [8] Zhang C, Cheng Y, Zhang S, et al. Changing epidemiology of hepatocellular carcinoma in Asia[J]. Liver Int,2022,42(9):2029-2041. [9] Chan S Y, Chang Y, Polpichai N, et al. Treatment with antihistamines and the risk of liver cancer in patients with viral hepatitis: a multi-center cohort study[J]. Viruses,2024,16(6):940. [10] Jacob R, Prince D S, Kench C, et al. Alcohol and its associated liver carcinogenesis[J]. J Gastroenterol Hepatol,2023,38(8):1211-1217. [11] Jiang W, Fu X, Wang G, et al. Effect of biliary tract invasion with obstructive jaundice on the prognosis of patients with unresectable hepatocellular carcinoma[J]. Acad Radiol,2023,30(3):483-491. [12] Liu H, Xiang Y, Zong Q B, et al. TDO2 modulates liver cancer cell migration and invasion via the Wnt5a pathway[J]. Int J Oncol,2022,60(6):1-13. [13] Deng Z, Liang S, Huang G, et al. Autophagy plays a pro-apoptotic role in arsenic trioxide-induced cell death of liver cancer[J]. J Integr Med,2024,22(3):295-302. [14] Wu Z H, Zhang H F, Li J Y, et al. Effectiveness and safety of brucea javanica oil assisted TACE versus TACE in the treatment of liver cancer: a systematic review and meta-analysis of randomized controlled trials[J]. Front Pharmacol,2024,15:1337179. [15] Li W, Lin M X, Lin X X, et al. Systematic Comparison of deep-learning based fusion strategies for multi-modal ultrasound in diagnosis of liver cancer[J]. Neuron,2024:128257. [16] Bertuzzi C, Germinario G, Righi S, et al. The role of peritumoral CD8+/TIA1+ lymphocytes in hepatocellular carcinoma aggressiveness and recurrence after surgical resection[J]. Pathol Res Pract,2022,237:154016. [17] Srivastava A, Sharma H, Chowdhury S, et al. Transforming growth factor-β mediated regulation of epigenome is required for epithelial to mesenchymal transition associated features in liver cancer cells[J]. Heliyon,2023,9(4):e14665. [18] Zheng J, Fan W, Zhang X, et al. PAIP1 regulates expression of immune and inflammatory response associated genes at transcript level in liver cancer cell[J]. PeerJ,2023,11:e15070. [19] Yuan R H, Hsu C L, Jhuang Y L, et al. Tumor-matrix interaction induces phenotypic switching in liver cancer cells[J]. Hepatol Int,2022,16(3):562-576. [20] Qiu S, Jin L, Yang D, et al. Clinical application value of hepatitis B virus basal core promoter 1762/1764 and GGTII and GGT in patients with HBV-DNA-positive primary liver cancer[J]. Medicine (Baltimore),2023,102(43):e35699. |